Radiopharmaceutical biomarkers and PET imaging have emerged as a valuable tool in the study of neurodegenerative diseases like PSP, particularly in the imaging of tau protein aggregates. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.